7 results on '"Adenocarcinoma of the gastroesophageal junction"'
Search Results
2. Near infrared ray-guided surgery using Firefly technology of the daVinci Xi system and intraoperative upper gastrointestinal endoscopy for subtotal gastrectomy and surgery for cancer of the gastroesophageal junction
- Author
-
Hiroyuki Sagawa, Masaki Saito, Sunao Ito, Shunsuke Hayakawa, Shohei Ueno, Tomotaka Okubo, Tatsuya Tanaka, Ryo Ogawa, Hiroki Takahashi, Yoichi Matsuo, Akira Mitsui, Masahiro Kimura, and Shuji Takiguchi
- Subjects
Near infrared ray ,Robotic surgery ,Tumor marking ,Gastric cancer ,Adenocarcinoma of the gastroesophageal junction ,Surgery ,RD1-811 - Abstract
Abstract Background In gastrectomies, especially subtotal gastrectomies and operations on the gastroesophageal junction, identifying the exact location of the tumor and establishing the appropriate resection line is very important. Accurate resection lines have a major impact on the preservation of organ function and curability. Preservation of as much as possible of the remaining stomach, including the fornix, may be an important surgical goal for maintaining an adequate postoperative quality of life. In adenocarcinoma of the gastroesophageal junction, the height of the esophageal dissection may affect reconstruction of the transhiatal approach. Methods We perform a new technique, near infrared ray-guided surgery, for the accurate localization of a tumor using the Firefly technology of the daVinci Xi system and intra-operative upper gastrointestinal endoscopy. We used this new technique for cases of upper gastric cancer or adenocarcinoma of the gastroesophageal junction. In this retrospective study, we examined to determine the extent (mm) of the tumor invasion of the esophagus, visualization of near infrared ray contained within endoscopic light, and distance from the proximal margin of the tumor to the surgical cut line on rapid histopathology and in the permanent preparation, including the operative videos and extracted specimens. Results We performed near infrared ray-guided surgery for 12 patients with gastric cancer or adenocarcinoma of the gastroesophageal junction, and the near infrared ray was clearly seen as green light with Firefly mode in all the patients. Near infrared ray-guided surgery was useful for obtaining localization of the tumor. In addition, it was possible to resect organ with adequate margins from tumor. Rapid intraoperative histopathological examinations confirmed that the resected specimens had negative margins. None of the patients required additional resection. Conclusions We believe that because near infrared ray-guided surgery can provide an accurate resection line, it will be useful for the resection of upper gastric cancer and adenocarcinoma of the gastroesophageal junction. It will also provide patients with a good postoperative quality of life after surgery.
- Published
- 2022
- Full Text
- View/download PDF
3. Near infrared ray-guided surgery using Firefly technology of the daVinci Xi system and intraoperative upper gastrointestinal endoscopy for subtotal gastrectomy and surgery for cancer of the gastroesophageal junction.
- Author
-
Sagawa, Hiroyuki, Saito, Masaki, Ito, Sunao, Hayakawa, Shunsuke, Ueno, Shohei, Okubo, Tomotaka, Tanaka, Tatsuya, Ogawa, Ryo, Takahashi, Hiroki, Matsuo, Yoichi, Mitsui, Akira, Kimura, Masahiro, and Takiguchi, Shuji
- Subjects
ESOPHAGOGASTRIC junction ,INFRARED radiation ,GASTRECTOMY ,FIREFLIES ,STOMACH cancer ,ONCOLOGIC surgery - Abstract
Background: In gastrectomies, especially subtotal gastrectomies and operations on the gastroesophageal junction, identifying the exact location of the tumor and establishing the appropriate resection line is very important. Accurate resection lines have a major impact on the preservation of organ function and curability. Preservation of as much as possible of the remaining stomach, including the fornix, may be an important surgical goal for maintaining an adequate postoperative quality of life. In adenocarcinoma of the gastroesophageal junction, the height of the esophageal dissection may affect reconstruction of the transhiatal approach.Methods: We perform a new technique, near infrared ray-guided surgery, for the accurate localization of a tumor using the Firefly technology of the daVinci Xi system and intra-operative upper gastrointestinal endoscopy. We used this new technique for cases of upper gastric cancer or adenocarcinoma of the gastroesophageal junction. In this retrospective study, we examined to determine the extent (mm) of the tumor invasion of the esophagus, visualization of near infrared ray contained within endoscopic light, and distance from the proximal margin of the tumor to the surgical cut line on rapid histopathology and in the permanent preparation, including the operative videos and extracted specimens.Results: We performed near infrared ray-guided surgery for 12 patients with gastric cancer or adenocarcinoma of the gastroesophageal junction, and the near infrared ray was clearly seen as green light with Firefly mode in all the patients. Near infrared ray-guided surgery was useful for obtaining localization of the tumor. In addition, it was possible to resect organ with adequate margins from tumor. Rapid intraoperative histopathological examinations confirmed that the resected specimens had negative margins. None of the patients required additional resection.Conclusions: We believe that because near infrared ray-guided surgery can provide an accurate resection line, it will be useful for the resection of upper gastric cancer and adenocarcinoma of the gastroesophageal junction. It will also provide patients with a good postoperative quality of life after surgery. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
- Author
-
Jomrich, Gerd, Kollmann, Dagmar, Ramazanova, Dariga, Ristl, Robin, Grose, Richard P., Ilhan-Mutlu, Aysegül, Preusser, Matthias, Fassnacht, Christina, Tsai, Yi-Chien, Guenova, Emmanuella, and Schoppmann, Sebastian F.
- Subjects
ESOPHAGOGASTRIC junction ,PEMBROLIZUMAB ,ESOPHAGEAL cancer ,PROGRAMMED cell death 1 receptors ,NEOADJUVANT chemotherapy ,PROGRAMMED death-ligand 1 ,CANCER chemotherapy - Abstract
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-1 and PD-L1 expression in adenocarcinomas of the gastroesophageal junction. PD-1 and PD-L1 expression in cancer cells and tumor-infiltrating lymphocytes in paired diagnostic biopsies and surgical specimens from patients with pretreated and curatively resected adenocarcinomas of the gastroesophageal junction were evaluated by immunohistochemistry. Paired tumor samples were available from 40 patients. PD-1 expression in cancer cells (p < 0.001; Exact Symmetry Test) and tumor-infiltrating lymphocytes (p < 0.001; Exact Symmetry Test) increased significantly after neoadjuvant therapy. Furthermore, we observed a significant decrease in PD-L1 expression in cancer cells (p = 0.003) after neoadjuvant therapy was observed. In this study we could show that tumor-cell expression of PD-1 and PD-L1 was significantly altered in patients with adenocarcinomas of the gastroesophageal junction after receiving neoadjuvant chemotherapy. Based on these observations, patients might profit from the combined use of cytotoxic chemotherapy and the blockade of the PD-1 axis. • The introduction of immunotherapy represents a paradigm shift in treating cancer. • A number of studies described synergism between cytotoxic chemotherapy and PD-1/PD-L1 immunotherapy. • Our findings suggest that combining cytotoxic chemotherapy with checkpoint inhibitors represents an beneficial option for AEG patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.
- Author
-
Jomrich, Gerd, Kollmann, Dagmar, Wilfing, Lavinia, Radosavljevic, Sanja, Ramazanova, Dariga, Ristl, Robin, Grose, Richard P., Ilhan-Mutlu, Aysegül, Preusser, Matthias, Fassnacht, Christina, Tsai, Yi-Chien, Guenova, Emmanuella, and Schoppmann, Sebastian F.
- Abstract
Summary: Background: The effects of cytotoxic chemotherapy on the expression of programmed death ligand 2 (PD-L2) are unknown and little is known about how the tumor microenvironment changes following neoadjuvant chemotherapy in locally advanced gastroesophageal adenocarcinomas (AEG). Recently, a number of studies reported that cytotoxic chemotherapy affects the expression levels of programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). Regarding PD-L2, the second known ligand of PD‑1, no data on potential changes in expression patterns in patients with preoperatively treated AEG are available. The aim of this study was to investigate the impact of cytotoxic chemotherapy on PD-L2 expression in patients with resectable AEG. Methods: Consecutive patients with locally advanced AEG treated with preoperative cytotoxic chemotherapy were included. PD-L2 expression by cancer cells (CCs) and tumor-infiltrating lymphocytes (TILs) was investigated in samples of paired diagnostic biopsies and resected tumor specimens by immunohistochemistry using two different anti-PD-L2 antibodies. Results: Included were 40 patients with AEG and available paired tumor tissue samples. PD-L2 expression was observed in one diagnostic biopsy sample by CCs and in one diagnostic biopsy sample by TILs. There was no difference concerning the expression levels measured by the two antibodies. Conclusion: In contrast to previously published studies reporting PD-L2 expression rates of up to 50% in AEGs, in our cohort, PD-L2 expression seems to play no significant role in AEG. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. 抗PD-1/PD-L1治疗在胃癌或胃食管结合部腺癌中的疗效荟萃分析.
- Author
-
张颖, 魏雨涵, 李莉, and 曹邦伟
- Subjects
- *
CLINICAL trials , *ESOPHAGOGASTRIC junction , *PROGRESSION-free survival , *PROGRAMMED cell death 1 receptors , *MONOCLONAL antibodies , *GROUP psychotherapy - Abstract
OBJECTIVE: To systematically evaluate the efficacy of programmed death-1/programmed death ligand-1( PD-1/PD-L1) monoclonal antibody in gastric cancer or adenocarcinoma of the gastroesophageal junction.METHODS: PubMed,Embase,the Cochrane Library database and abstracts of American society of clinical oncology( ASCO) conferences in the past three years,and European society for medical oncology( ESMO) conferences in 2020 were retrieved to collect the prospective studies,phase Ⅱ and phase Ⅲ clinical trials( the study group was treated with PD-1/PD-L1 monoclonal antibody alone or in combination with chemotherapy,while the control group received chemotherapy or placebo. The retrieval deadline was Sept. 26 th,2020. The efficacy of different treatment regimens( PD-1/PD-L1 monoclonal antibody treatment group compared with chemotherapy group,PD-1/PD-L1 monoclonal antibody treatment + chemotherapy group compared with chemotherapy group,and PD-1/PD-L1 monoclonal antibody treatment group compared with placebo group) was assessed by subgroup analysis,and forest plotting was performed by Stata SE 12 software. RESULTS: Seven clinical trials were ultimately enrolled,including three original papers,two abstracts of ASCO conferences and two abstracts of ESMO conferences.( 1) The differences in overall survival( OS)( HR = 0. 96,95% CI = 0. 87-1. 07,P = 0. 451) and objective response rate( ORR)( RR = 0. 65,95% CI = 0. 39-1. 09,P = 0. 102) between the PD-1/PD-L1 monoclonal antibody treatment group alone and the chemotherapy group were not statistically significant,yet the difference in progression free survival( PFS) between two groups was statistically significant( HR = 1. 45,95% CI = 1. 17-1. 81,P = 0. 001).( 2) The differences of OS( HR = 0. 84,95% CI = 0. 76-0. 94,P = 0. 001),PFS( HR = 0. 78,95% CI = 0. 70-0. 86,P = 0. 000) and ORR( RR = 1. 24,95% CI = 1. 10-1. 39,P = 0. 000) between the PD-1/PD-L1 monoclonal antibody treatment + chemotherapy group and the chemotherapy group were statistically significant.( 3) The differences of OS( HR = 0. 63,95% CI = 0. 51-0. 78,P = 0. 000),PFS( HR = 0. 60,95% CI = 0. 49-0. 75,P = 0. 000) and ORR( RR = 29. 93,95% CI = 1. 84-485. 72,P = 0. 017)between the PD-1/PD-L1 monoclonal antibody treatment group and the placebo group were statistically significant.CONCLUSIONS: The results of this study suggest that PD-1/PD-L1 monoclonal antibody combined with chemotherapy may benefit patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.Compared with placebo,PD-1/PD-L1 monoclonal antibody alone also benefits patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction. However,compared with chemotherapy,patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction may not get a more significant treatment effect from PD-1/PD-L1 monoclonal antibody,and more evidence is needed to confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Cystathionine β-synthase expression correlates with tumor development and poor prognosis in patients with adenocarcinoma of the gastroesophageal junction.
- Author
-
Liu GJ, Hu XJ, Huo BJ, Yue M, Liu F, and Chang L
- Abstract
Objectives: To reveal the expression level of cystathionine β-synthase (CBS) in adenocarcinoma of esophagogastric junction (AEG) and discuss the relationship between CBS expression level and tumor microvascular density (MVD), clinical features and prognosis., Methods: Paraffin samples from 214 patients with AEG were selected to make pathological microchips. Immunohistochemistry was performed based on the microchips to detect the expression level of CBS and microvascular density (MVD) in cancer tissues and adjacent control tissues. Relationships between expression level of CBS and MVD, clinical characteristics and prognosis were analyzed., Results: In total, 214 AEG cases were classified into three groups: CBS negative staining ( n =26), low staining ( n =44), and high staining ( n =144). Quantitative alterations in CBS and CD31 expression were explored using immunohistochemistry. The 5-year recurrence rate of enrolled patients was followed up and found that CBS expression was significantly increased in tumor tissue compared with adjacent non-tumor tissue ( P <0.0001). There were significant differences in microvascular density between the groups with negative and high CBS staining ( P <0.0001), and between the groups with low and high CBS staining ( P <0.0001). Univariate analysis revealed significant differences in tumor stage ( P <0.0001), T stage ( P =0.008), N stage ( P =0.028), differentiation degree ( P =0.037), and 5-year survival ( P =0.0034) among the three groups. Multivariate logic regression analysis showed that increased CBS scores were associated with an increased probability of 5-year recurrence ( P =0.018). Finally, different CBS expression levels were associated with disease-free survival in AEG patients., Conclusions: CBS expression level is closely related to microvascular density and tumor stage in AEG. High level of CBS not only accelerates tumor angiogenesis but also affects patient's survival and prognosis., Competing Interests: None., (AJTR Copyright © 2022.)
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.